Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy - 09/08/11
, Jean-Pierre Bassand, MD b, Susan Chrolavicius, BScN a, Rafael Diaz, MD c, Keith A.A. Fox, MBChB d, Christopher B. Granger, MD e, Sanjit Jolly, MD a, Hans-Jurgen Rupprecht, MD f, Petr Widimsky, MD g, Salim Yusuf, MBBS, DPhil aon behalf of the CURRENT OASIS 7 Steering Committeeh
Résumé |
Background |
Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non–ST-segment-elevation acute coronary syndromes (ACS). Recent mechanistic and clinical data suggest that higher loading and maintenance doses of clopidogrel may achieve a more rapid and greater degree of platelet inhibition that translates into improved clinical outcomes, but this is yet to be formally evaluated in an adequately powered randomized trial.
Objectives |
To evaluate the efficacy and safety of (1) a higher loading and initial maintenance dose of clopidogrel compared with the standard-dose regimen and (2) high-dose ASA compared with low-dose ASA in patients with ST or non–ST-segment-elevation ACS managed with an early invasive strategy.
Design |
Multicenter, international, randomized, 2×2 factorial design trial evaluating a clopidogrel high-dose regimen (600 mg loading dose on day 1 followed by 150 mg once daily on days 2 to 7, followed by 75 mg once daily on days 8-30) compared with the standard-dose regimen (300 mg loading dose on day 1, followed by 75 mg once daily on days 2-30) and high-dose ASA (300-325 mg daily) versus low-dose ASA (75-100 mg daily) in patients with ST or non–ST-segment-elevation ACS managed with an early invasive strategy. The clopidogrel dose comparison is double-blind and the ASA dose comparison is open-label. The primary outcome is the composite of death from cardiovascular causes, myocardial (re)infarction or stroke up to day 30. The primary safety outcome is major bleeding. The sample size is 18,000 to 20,000 patients.
Conclusions |
The CURRENT-OASIS 7 trial will help to define optimal dosing regimens for clopidogrel and ASA in patients with ST and non–ST-segment-elevation ACS treated with an early invasive strategy.
Le texte complet de cet article est disponible en PDF.Plan
| Registered Clinical Trial Number: NCT00335452. |
|
| Guest Editor: Mauricio G. Cohen, MD. |
Vol 156 - N° 6
P. 1080 - décembre 2008 Retour au numéro
Article précédent
- Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics
- Robert E. Ratner, Christopher P. Cannon, Hertzel C. Gerstein, Richard W. Nesto, Patrick W. Serruys, Gerrit-Anne van Es, Nikheel S. Kolatkar, Barbara G. Kravitz, Andrew Zalewski, Peter J. Fitzgerald, The APPROACH study group
- Intraobserver variability in grading severity of repeated identical cases of mitral regurgitation
- Nicholas Thomas, Beth Unsworth, Emily A. Ferenczi, Justin E. Davies, Jamil Mayet, Darrel P. Francis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?